Scimago Lab
powered by Scopus
Formerly the IP & Science
business of Thomson Reuters


eISSN: 2329-0358

Get your full text copy in PDF

Ex-VivoHemoperfusion(eHPS)of Pig-Lungs with Whole Human Blood: Effectsof Complement Inhibitionwith a Soluble CI-Esterase-I nhibitor

H. Schelzig, F. Simon, C. Krischer, A. Vogel, D. Abendroth

Ann Transplant 2001; 6(3): 34-39

ID: 497680

Objectives: Xenotransplantation could be a future alternative to allotransplantation due to increasing organ shortage. Complement activation plays a major role in hyperacute rejection (HAR) in pig-to-human combinations. We developed an ex-vivo hemoperfusion (EHP) system to investigate pathophysiology of HARin the lung. After standardizing the model, the effect of a soluble complement inhibitor (C I-INH, Berinert'M) was investigated. Methods: Pig lungs were harvested following cold perfusion with Celsior'M preservation solution. EHP was performed using fresh heparinized human blood plus C I-INH (n=6) or heparinized human blood as control (n=4). Bloodgas analyses (BGA), pulmonalarterial pressure (PAP) were monitored. P-selectin and L-selectin were measured. Tissue samples were taken and microscopic changes evall!ated. Results: BGA, PAP, macroscopic and microscopic changes in the control group showed HAR, while the C I-INH group showed significantly longer function. Leucocytes and platelets were markedly activated in the control, wereas in the treated group L-selectin and P-selectin values indicated lower activation. HE stainings showed maintained lung architecture after perfusion of pig-lungs with human blood plus C I-INH. Immunohistochemistry showed less C Iq, C3, CSb-9 activation in the C I-INH group. Conclusions: Investigation of interaction of human blood with pig lung endothelium could be done in this model. C I-INH attenuates HAR in a pig-to-human lung transplantation model by decreasing the activation of adhesion molecules. C I-INH could playa role in induction therapy of future lung xenotransplantation.

This paper has been published under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
I agree